

# Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

NCT07250269

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Gracell Biotechnologies (Shanghai) Co., Ltd.
Enrollment	9 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Confirmed histopathological diagnosis of AL amyloidosis
- One or more organs currently or historically impacted by AL amyloidosis according to consensus guidelines
- Measurable hematologic disease: dFLC  $\geq$  20 mg/L or serum M-protein  $\geq$  5g/L
- Relapsed disease or refractory disease defined as a need for additional therapy after at least 1 line of anti-plasma cell-directed therapy.
- ECOG performance status of 0 to 1
- ... and 2 more (see full listing online)

### Exclusion (15)

- Have any other form of amyloidosis other than AL amyloidosis
- Mayo Stage IIIb AL amyloidosis
- Oxygen saturation  $<$  95% on room air
- Systolic blood pressure  $<$ 100mmHg
- Mayo Stage IIIb AL amyloidosis (Wechalekar, 2013)
- ... and 10 more (see full listing online)

## Locations (9 total)

---

Research Site, Beijing, China  
Research Site, Beijing, China  
Research Site, Beijing, China  
... and 6 more locations